Bristol-Myers Squibb, Pfizer Report Results of Phase III Aristotle Trial of Eliquis

Bristol-Myers Squibb and Pfizer have released an analysis of the results of a Phase III trial of their blood-thinner Eliquis. The drug was being evaluated for efficacy in prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation or atrial flutter.
Pharmaceutical Business Review